

DOCKET NO: ISIS0064-100 (RTS-0175)**PATENT****In the Claims:**

Please amend claim 1 and add new claims 21-30 as follows.

1. (previously presented) An oligomeric compound comprising up to 50 8 to 50 nucleobases in length and comprising SEQ ID NO:38 ~~targeted to a nucleic acid molecule encoding human dual specific phosphatase 5 (SEQ ID NO:10), wherein said compound inhibits the expression of human dual specific phosphatase 5 by at least 40%.~~
2. (Original) The compound of claim 1 which is an antisense oligonucleotide.
3. (Canceled).
4. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
5. (Original) The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.
6. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
7. (Original) The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
8. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
9. (Original) The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

DOCKET NO: ISIS0064-100 (RTS-0175)**PATENT**

10. (Original) The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
11. (Canceled).
12. (Original) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
13. (Original) The composition of claim 12 further comprising a colloidal dispersion system.
14. (Original) The composition of claim 12 wherein the compound is an antisense oligonucleotide.
15. (Previously presented) A method of inhibiting the expression of dual specific phosphatase 5 in cells or tissues comprising contacting said cells or tissues *in vitro* with the compound of claim 1 so that expression of dual specific phosphatase 5 is inhibited.
- 16-20. (Canceled).
21. (new) A compound consisting of SEQ ID NO:38.
22. (new) The compound of claim 21 which is an antisense oligonucleotide.
23. (new) The compound of claim 22 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
24. (new) The compound of claim 23 wherein the modified internucleoside linkage is a phosphorothioate linkage.

DOCKET NO: ISIS0064-100 (RTS-0175)**PATENT**

25. (new) The compound of claim 22 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
26. (new) The compound of claim 25 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
27. (new) The compound of claim 22 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
28. (new) The compound of claim 27 wherein the modified nucleobase is a 5-methylcytosine.
29. (new) The compound of claim 22 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
30. (new) The compound of claim 1 wherein the compound comprises up to 30 nucleobases.